Fact CheckerSign in

NCT07897734Not yet recruitingPhase 1/2

TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 (RAS Inhibitor) in Patients With MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer With RAS Mutation

Source: ClinicalTrials.gov · Last updated 27 Oct 2026

Brief summary (registry, in English)

TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
188 (estimated)
First submitted
20 Oct 2026
Start date
Nov 2026
Primary completion date
Nov 2031
Lead sponsor
Tango Therapeutics, Inc.
NCT number
NCT07897734

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 188
  • From Nov 2026 to the primary completion date, Nov 2031
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has received prior treatment with a PRMT5 inhibitor, MAT2A inhibitor or RAS inhibitor.

Other illness

  • Has an active infection requiring systemic therapy.
  • Any condition that may impact the ability to take or absorb study drugs

Other

  • Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms

Who the study is looking for

  • Is ≥18 years of age at the time of signature of the main study ICF.
  • Has an ECOG PS of 0 or 1.
  • Has loss of the MTAP gene, documented by a validated assay
  • Has one of the following disease characteristics:
    • 1L or 2L metastatic PDAC
    • Locally advanced, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only).
  • Has evidence of measurable disease based on RECIST v1.1.
  • Adequate organ function

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.